• Home
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Services
    • Proteomics
    • Genomics Transcriptomics
    • Flow Cytometry
    • Assay Development
    • Monoclonal Antibodies
    • Biobanking
    • Custom Kit Production
    • OLINK Services
    • Biomarker Data Analyses
  • R&D
  • Products
    • MEMORYLINC
    • NEUROLINCS
    • FIMICS
    • BIOPRED
    • IVD Products
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
  • IFU APO-Easy
  • Copy of IFU APO-Easy
  • Stability APO-Easy
  • APO-Easy-FLS-OE02-01
  • APO-Easy-FLS-OE02-02
  • APO-Easy-FLS-OE02-03
Contact
Firalis
  • Home
  • About
  • Services
  • Products
  • R&D
  • Quality
  • Investors
  • Media
  • 123-olink-services-new-16871652741568.png

    OLINK Services (Explore, Target & Flex)

    comprehensive overview of protein expression levels on Olink® Explore, Target and Flex platforms!

  • 123-proteomics-services-new-16871653187989.jpeg

    PROTEOMICS Services

    Absolute protein quantification, ultra-low quantification (Quanterix™), large-scale protein identification (Olink®)

  • 123-genomics-services-new-16871653450163.png

    GENOMICS Services

    Next Generation Sequencing, Single cell sequencing, Spatial Transcriptomics and custom RT-qPCR

  • 123-assay-development-services-new-16871653717555.png

    ASSAY DEVELOPMENT & PRODUCTION

    We provide assay development services and produce biological material and IVD kits.

  • 123-brkikonp0kq.jpg

    NEUROLINCS

    targeted sequencing panel that quantifies ~7500 brain enriched lncRNAs associated with cognitive impairment, Alzheimer's, and other neurodegenerative diseases

  • 776-hybxy5phqr8.jpg

    BIOPRED

    an mRNA based targeted gene sequencing panel to better understand inflammatory-autoimmune disorders

  • 776-rg1lnufgjhi.jpg

    FIMICS

    a long non-coding RNA panel to better characterize patients with cardiac disorders and toxicities

  • 776-rkjyubm92mm.jpg

    ELISA KITS

    Colorimetric sandwich ELISA kits developed and validated for biomarker measurement in blood-derived matrices samples

the reliable partner

since its creation, Firalis has been awarded for and contributed in

100+ clinical and pre-clinical research projects in biomarkers,

playing a leading role towards the setting of industry gold standards

for the discovery, development and qualification of

novel biomarkers for clinical and pre-clinical applications!

126-whyfiralis.png

Why Firalis

Firalis has a comprehensive range of know-how for biomarker discovery up to clinical qualification, develops and commercializes biomarker tests, RUO and IVD tools.

129-whoweare.png
Who we are

Firalis projects target qualification of biomarkers  for various clinical applications.

As the initiator of SAFE-T consortium, Firalis validates and develops biomarker panels, following strictly EMA and FDA directions.

030548264132-whatwedo.png

What we do

Our production facilities are GMP compliant, certified "ISO 13485" for medical device manufacture, and "ISO 17025",

being the most important quality standard

for calibration and testing.

Recent news at Firalis

Autoimmune project, PARADISE, holds first plenary to highlight six months of project progress

07.11.2023

Read More

COVIRNA Project Final Conference takes place on 19-April-23

COVIRNA Project end date is approaching, with the final conference that will take place in Brussels on the 19th of April, 2023.

07.04.2023

Read More

PARADISE Project launches with a kick-off held in Dublin (3-4 April 2023)

To develop a personalised prediction tool for better management of autoimmune diseases recurrence, PARADISE Project kicked off on 3 -4 April 2023 in Dublin, coordinated by ADAPT at Trinity College of Dublin, with partners across several European institutions, including FIRALIS.

05.04.2023

Read More

Bpifrance funds Firalis’ Alzheimer Project!

FIRALIS’ Research on Neurodegenerative Diseases obtains Bpifrance Funding!

09.08.2022

Read More

Load More

Contact Firalis

Firalis Group

© Copyright 2020 all rights reserved. 

The company logos, products and service marks are trademarks or registered trademarks of Firalis.

-----------------------------------------------------------------------------------------------------------------------

Information addressed to health professionals. The products presented on this site are for professional use only and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

-----------------------------------------------------------------------------------------------------------------------

Headquarter : 17 Rue du Fort 68330 Huningue FRANCE